Stanford researchers have discovered RNA signatures that can be used to predict patient outcomes and identify optimal treatments in acute myeloid leukemia.
Researchers in the Roncarolo have discovered transcription factors that enable the tracking and differentiation of type 1 T regulatory (Tr1) cells for the treatment of autoimmune conditions.
IPEX syndrome is a severe autoimmune disease with limited treatment options caused by mutations in the forkhead box protein 3 (FOXP3) gene, which plays a critical role in immune regulation.
Engineered cytotoxic T cells are a promising class of cell therapies. These living drugs are capable of selectively killing blood cancers, such as acute myeloid leukemia (AML), and delaying its progression.